semaglutide off the shortage list As of February 21, 2025, FDA updated its drug list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A Novo's Wegovy and Ozempic removed

Variety of delivery options including next day & free delivery

Understanding these stages prevents the most common mistake new users make, which is assuming the medication is not effective simply because they do not feel different yet

Regular Monitoring Recommended Lab work may be required to monitor glucose, kidney function, and nutrient levels during therapy

Failure to Adequately Warn Patients About Known Risks The master complaint filed in MDL 3094 alleges that Novo Nordisk and Eli Lilly knew or should have known about the severe gastroparesis and vision loss risks associated with their GLP-1 medications but failed to provide adequate warnings on product labels, marketing materials, or prescribing information

In comparison, medications like semaglutide, with a longer half-life, stay for a long time in the body and only need to be taken once weekly

In SURMOUNT-1, 91% lost at least 5%, 79% lost at least 15%, and 36% lost at least 25%